Some characteristics of patients with myelodysplastic syndrome
https://doi.org/10.21886/2219-8075-2020-11-4-32-42
Abstract
Objective: epidemiological analysis of myelodysplastic syndrome, based on the available retrospective data.
Materials and methods: a retrospective analysis of the medical history data of 115 patients (61 men and 54 women) with a diagnosis of myelodysplastic syndrome who received treatment in the hematology department of the «City Hospital № 7 of the city of Rostov-on-Don» in the period from 2010 to 2019.
Results: the most likely comorbidities were cardiovascular diseases, which are the main cause of sudden death, and endocrine diseases, which together influence the outcome of myelodysplastic syndrome.
Conclusions: there are no individual risk assessment algorithms that could determine the goal setting of therapy in patients with myelodysplastic syndrome, whose life expectancy depends more on the course of concomitant diseases.
About the Authors
P. V. Lipilkin
Don State Technical University
Russian Federation
Russian Federation
assistant of the Department of Biology and general pathology,
Rostov-on-Don
Yu. V. Shatokhin
Rostov State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), professor of the Department of Hematology and Transfusiology with courses in clinical laboratory diagnostics, genetics and laboratory genetics of faculty of professional development and training,
Rostov-on-Don
A. A. Matsuga
Rostov State Medical University;
City Hospital № 7
Russian Federation
Russian Federation
assistant of the Department of Hematology and Transfusiology with a Сourse of Сlinical Laboratory Diagnostics, Genetics and Laboratory Genetics;
MD of the Department of Hematology,
Rostov-on-Don
References
1. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45-52. doi: 10.1182/blood-2008-01-134858
2. Cogle CR. Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2015;10(3):272-81. doi: 10.1007/s11899-015-0269-y
3. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, et al. Agerelated mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472-8. doi: 10.1038/nm.3733
4. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477- 87. doi: 10.1056/NEJMoa1409405
5. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65. doi: 10.1182/blood-2012-03-420489.
6. Avgerinou C, Giannezi I, Theodoropoulou S, Lazaris V, Kolliopoulou G, et al. Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece. Hematology. 2017;22(7):419-429. doi: 10.1080/10245332.2016.1277006
7. Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res. 2011;35(12):1591-6. doi: 10.1016/j.leukres.2011.06.001
8. Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29(4):428-34. doi: 10.1200/JCO.2010.31.3080
9. Du Y, Fryzek J, Sekeres MA, Taioli E. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res. 2010;34(1):1-5. doi: 10.1016/j.leukres.2009.08.006
10. Schmalzing M, Aringer M, Bornhäuser M, Atta J. Myelodysplastisches Syndrom, akute Leukämie und Stammzelltransplantation [Myelodysplastic syndrome, acute leukemia and stem cell transplantation]. Z Rheumatol. 2017;76(Suppl 2):26- 32. (In German). DOI: 10.1007/s00393-017-0369-2
11. Falantes JF, Calderón C, Márquez Malaver FJ, Alonso D, Martín Noya A, et al. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories. Clin Lymphoma Myeloma Leuk. 2013;13(2):144-52. DOI: 10.1016/j.clml.2012.09.013
12. Falantes JF, Garcia-Manero G. Does the concept of lower-risk myelodysplastic syndrome need to be revisited? Leuk Res. 2015;39(10):1003-5. DOI: 10.1016/j.leukres.2015.06.010
13. Bruneau J., Molina T.J. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. In: van Krieken J. (eds) Encyclopedia of Pathology. Encyclopedia of Pathology. Springer, Cham. – 2019. DOI: 10.1007/978-3-319-28845-1_3817-1
14. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88. PMID: 9058730.
15. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-603. DOI: 10.1200/JCO.2005.01.7038
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8
17. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441-9. DOI: 10.3324/haematol.2010.033506
18. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S; Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003;27(11):1765- 72. DOI: 10.1097/01.ALC.0000093743.03049.80
19. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev. 2006;(2):CD002235. doi: 10.1002/14651858.CD002235.pub2.
20. Ricci S, Celani MG, Cantisani AT, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev. 2006;(2):CD000419. doi: 10.1002/14651858.CD000419.pub2
21. Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;(2):CD001011. doi: 10.1002/14651858.CD001011
22. Al Hajeri AA, Fedorowicz Z, Omran A, Tadmouri GO. Piracetam for reducing the incidence of painful sickle cell disease crises. Cochrane Database Syst Rev. 2007;(2):CD006111. DOI: 10.1002/14651858.CD006111.pub2
23. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498. DOI:10.1056/NEJMoa1408617
24. Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol. 2013;31(21):2671-7. doi: 10.1200/JCO.2012.48.0764
25. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842-847. doi: 10.1126/science.aag1381
26. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377(2):111-121. doi: 10.1056/NEJMoa1701719
27. Musikhina N.A., Gapon L.I., Petelina T.I., Makhneva E.A., Emeneva I.V. Endothelial dysfunction and heart rate variability in patients with arterial hypertension and coronary artery disease. “Arterial’naya Gipertenziya” (“Arterial Hypertension”). 2016;22(4):414-424. (In Russ.) DOI:10.18705/1607-419X-2016-22-4-414-424
28. Falantes JF, Márquez-Malaver FJ, Knight T, Calderón-Cabrera C, Martino ML, et al. The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome. Leuk Lymphoma. 2017;58(8):1893-1902. DOI: 10.1080/10428194.2016.1267350
29. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116(9):2174-9. DOI: 10.1002/cncr.24984
30. Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016;375(21):2023- 2036. DOI: 10.1056/NEJMoa1605949
31. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17. DOI: 10.1182/blood-2018-08-868752
32. Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392(10145):387-399. DOI: 10.1016/S0140-6736(18)31133-4
33. Luzina E.V., Lareva N.V., Zhilina A.A., Zhigzhitova E.B., Ustinova E.E. The erosive ulcerous lesions of upper part of gastrointestinal tract in patients with ischemic heart disease: treatment and prevention. Medical Journal of the Russian Federation. 2017;23(6):327-330. (In Russ.) DOI: 10.18821/0869-2106-2017-23-6-327-330
34. Tomaszewski M, White C, Patel P, Masca N, Damani R, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatographytandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855-61. DOI: 10.1136/ heartjnl-2013-305063
35. Ector GICG, Govers TM, Westerweel PE, Grutters JPC, Blijlevens NMA. The potential health gain and cost savings of improving adherence in chronic myeloid leukemia. Leuk Lymphoma. 2019;60(6):1485-1492. DOI: 10.1080/10428194.2018.1535113
36. Hall AE, Paul C, Bryant J, Lynagh MC, Rowlings P, et al. To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol. 2016;97:247-62. DOI: 10.1016/j.critrevonc.2015.08.025
37. Kekäle M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M. Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Prefer Adherence. 2014;8:1619-27. DOI: 10.2147/PPA.S70712
38. Yeoh A, Collins A, Fox K, Shields S, Ritchie P, et al. Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2017;34(1):38-42. DOI: 10.1080/08880018.2016.1276235
39. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348(9024):383-6. DOI: 10.1016/s0140-6736(96)01073-2
40. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2019;1(1):CD009009. DOI: 10.1002/14651858.CD009009.pub3
41. Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to “save lives”--and what we can do about it. BMJ. 2016;352:h6080. doi: 10.1136/bmj.h6080
42. Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol. 2005;23(2):293-300. DOI: 10.1200/JCO.2005.06.107
43. Zahl PH, Jørgensen KJ, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer. 2013;109(7):2014-9. DOI: 10.1038/bjc.2013.427
44. Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, et al. Screening and prostate-cancer mortality in a randomized european study. The New England Journal of Medicine. 2009;360(13):1320-28. DOI:10.1056/NEJMoa0810084
45. Draisma G, Boer R, Otto SJ., van der Cruijsen IW, Damhuis RAM, et al.. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. Journal of the National Cancer Institute. 2003;95(12):868-78. DOI:10.1093/jnci/95.12.868
46. Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stemcell transplantation. J Clin Oncol. 2014;32(25):2691-8. DOI: 10.1200/JCO.2013.52.3381
47. Gill H, Leung AY, Kwong YL. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. Int J Mol Sci. 2016;17(4):440. DOI: 10.3390/ijms17040440
48. Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126(21):2355-61. DOI: 10.1182/blood-2015-08-667063
49. Savchenko V.G., Parovichnikova E.N., Kokhno A.V., Semochkin S.V., Afanasyev B.V., et al. National clinical guidelines for the diagnosis and treatment of myelodysplastic syndromes in adults. Russian journal of hematology and transfusiology. 2016;61(1S (4)):3-5. (In Russ.) eLIBRARY ID: 21689282
50. Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMO Guidelines Working Group. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii57-69. DOI: 10.1093/annonc/mdu180
Review
For citations:
Lipilkin P.V., Shatokhin Yu.V., Matsuga A.A. Some characteristics of patients with myelodysplastic syndrome. Medical Herald of the South of Russia. 2020;11(4):32-42. (In Russ.) https://doi.org/10.21886/2219-8075-2020-11-4-32-42
Views:
2181
Email this article 